https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-09-19 / Cancers (Basel) 2019 Sep;11(9)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-09-19 / Cancers (Basel) 2019 Sep;11(9)2019-09-19 00:00:002019-09-19 00:00:00Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-09-11 / Front Oncol 2019;9:884
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-09-11 / Front Oncol 2019;9:8842019-09-11 00:00:002019-09-11 00:00:00Past, Current, and Future of Immunotherapies for Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-08-30 / Biomedicines 2019 Aug;7(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-08-30 / Biomedicines 2019 Aug;7(3)2019-08-30 00:00:002021-11-15 13:22:59Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-08-14 / Front Immunol 2019;10:1939
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-08-14 / Front Immunol 2019;10:19392019-08-14 00:00:002023-03-07 12:33:09Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)2019-06-17 11:50:402019-07-17 11:53:03Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-29 / Int. J. Cancer 2019 10;145(7):1958-1969
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-29 / Int. J. Cancer 2019 10;145(7):1958-19692019-04-29 00:00:002020-08-26 14:13:53Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-02-06 / Front Oncol 2019;9:50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-02-06 / Front Oncol 2019;9:502019-02-06 00:00:002019-02-06 00:00:00On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-01-01 / Klin Onkol 2019;32(1):70-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-01-01 / Klin Onkol 2019;32(1):70-742019-01-01 00:00:002019-01-01 00:00:00Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Front Immunol 2018;9:2759
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Front Immunol 2018;9:27592018-12-05 00:00:002018-12-05 00:00:00Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-11-14 / Clin Transl Med 2018 Nov;7(1):35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-11-14 / Clin Transl Med 2018 Nov;7(1):352018-11-14 00:00:002018-11-14 00:00:00Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
